Kategoria: Tutkimus

Roche/Genentech päivitys GENERATION HD2 -tutkimuksesta

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Novartis lopettaa VIBRANT-HD-tutkimuksen

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]

uniQure ilmoitti jatkavansa potilasrekisteröintiä AMT-130-tutkimukseen korkeammalla annostasolla.

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

Wave Life Sciences julkisti positiivisen päivityksen vaiheen 1b/2a SELECT-HD-tutkimuksesta, jonka ensimmäiset tulokset osoittavat, että WVE-003:lla on Allele-Selective Target Engagement -testi Huntingtonin taudissa

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

uniQure julkisti päivityksen pienen annoksen kohortista vaiheen I/II kliinisessä tutkimuksessa AMT-130-geeniterapian käytöstä Huntingtonin taudin hoidossa.

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Annexon Biosciences päivittää tutkimustuloksia

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Webinaari - Kaikki mitä sinun tarvitsee tietää Proof-HD:stä

Yesterday, Prilenia hosted a webinar updating on the Phase III trial with Pridopidine. Thank you to everyone who join and a special thanks to our speakers, Michael Hayden, Andrew Feigin, […]

Breaking News - Roche suunnittelee uutta Tominersen-tutkimusta

Some encouraging news has just come in from Roche.  Analysis of the results of Roche’s Phase III GENERATION HD1 trial, which was stopped in March 2021, has found that a […]